SPINRAZA(R) (nusinersen) Approved in the European Union
First Approved Treatment in EU for SMA
Approved to Treat Broad Range of People with SMA
Ionis Earns $50 Million Milestone
CARLSBAD, Calif., June 1, 2017 -- (Healthcare Sales & Marketing Network) -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) annou... Biopharmaceuticals, Regulatory Ionis Pharmaceuticals, SPINRAZA, nusinersen, spinal muscular atrophy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news